Renal Hemodynamic Effects of RLX030A in Subjects With Chronic Heart Failure (CHF)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 118 participants.

Also called NCT01546532

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 118 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01546532
  • EudraCT 2011-001588-37
Other papers using this trial's data
  • Renal hemodynamic effects of serelaxin in patients with chronic heart failure: a randomized, placebo-controlled study Circulation. Heart failure, 2014-11 DOI, PubMed 25286914

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Germany, Netherlands, Poland (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01546532. Randomized; quadruple masking; primary purpose treatment. Start 2012-02 (registry gives no type); primary completion 2012-12 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Renal Hemodynamic Effects of RLX030A in Subjects With Chronic Heart Failure (CHF)
Condition
Chronic Heart Failure (CHF)
Intervention (Drug)
RLX030
Intervention (Drug)
Placebo
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct01546532
Content hash
e1c18fe7f29934b44741ec5a39f5d267a4e15f2f5e14cbb3de902af2486f5622